NIH Reference Number
E-295-2012
Product Type
- Therapeutics
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
- Taryn Dick
Description of Technology
Scientists at the National Cancer Institute's Molecular Targets Laboratory have discovered that Cnidarins as a novel class of highly potent proteins capable of blocking the HIV virus from penetrating T-cells. Cnidarins were found in a soft coral collected in waters off Australia's northern coast. Cnidarins can block virus fusion/entry but do not block viral attachment. In addition, Cnidarins do not have lectin-like activity and therefore possibly a unique mechanism of action. Thus, Cnidarins may represent important new leads for HIV microbicides or for systemic therapeutics for HIV.
Potential Commercial Applications
Microbicide, Therapeutic, Research tool
Competitive Advantages
- High potency against HIV
- Novel Chemical composition
- Family of related proteins
- Unique mechanism of action
Inventor(s)
Barry OKeefe (NCI), James McMahon (NCI), Koreen Ramessar (NCI), Chang-yun Xiong (NCI)
Development Stage
- Pre-clinical (in vivo)
Patent Status
- U.S. Patent Filed: U.S. Patent Application Number PCT US1510797
Therapeutic Area
- Infectious Diseases
Updated
Monday, March 26, 2018